Piramal buys Coldstream Labs for Rs 180 cr

P T Jyothi Datta Mumbai | Updated on January 24, 2018 Published on January 17, 2015


Piramal Enterprises Ltd has invested $30.65 million (about Rs 180 crore) towards acquiring Coldstream Laboratories Inc, a speciality pharmaceutical contract manufacturer.

The transaction was done through Piramal Enterprises Ltd’s (PEL) wholly owned subsidiary in the United States, in an all cash deal, a note from the company said.

Of the total amount invested, about $5.65 million would be towards the purchase of the facility building which is currently leased to Coldstream, while the rest would be towards purchase of 100 per cent of the company’s shares, it added.

Coldstream is a contract development and manufacturing organisation focused on the development and manufacturing of sterile injectable products.

Founded in 2007, it is majority owned by University of Kentucky Research Foundation (an affiliate of the University of Kentucky), the note said.

Coldstream is a specialty pharmaceutical contract manufacturer with an emphasis on clinical trials to commercial-scale manufacturing of sterile liquid and lyophilised parenterals and injectables. It has developed differentiated expertise to formulate and manufacture high potency and cytotoxic compounds, including Antibody Drug Conjugates (ADCs).

The company operates from an FDA approved facility located in Lexington, Kentucky, USA. Revenues of Coldstream over the last three years are about $14 million (2014E) and it employs about 91 people.

Vivek Sharma, Chief Executive of Piramal Enterprises' Pharma Solutions business', said: “Coldstream is a very high quality operation and has been able to build significant customer relationships and track record for sterile products. We see this as a great platform for growth in our pharma solutions business. This acquisition allows PEL to move further into the injectable market segment and should have strong synergy with our existing pharma solutions business. Our strong capabilities in sterile product development and in ADC product segment will allow us to offer an integrated solution to our customers.”

Piramal Enterprises has been flush with funds after it sold its domestic formulations business for Rs 17,000 crore to Abbott, followed by the sale of its diagnostics business for over Rs 600 crore to Super Religare Laboratories — both in 2010.

Published on January 17, 2015

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.